Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-sponsored, open-label, single dose, safety and tolerability study clinical study of a Durasert implant to treat severe OA of the knee.

Next Previous
X
Search
Trial Profile

An investigator-sponsored, open-label, single dose, safety and tolerability study clinical study of a Durasert implant to treat severe OA of the knee.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions

    • Most Recent Events

    • 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. changed its name to EyePoint Pharmaceuticals.
    • 14 Dec 2017 According to pSivida media release, Dr. Mark P. Figgie, Chief of the Surgical Arthritis Service at Hospital for Special Surgery is the principal investigator of the study.
    • 14 Dec 2017 Results published in the pSivida Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top